Marker Therapeutics (MRKR) Liabilities from Discontinued Operations (2022 - 2023)
Marker Therapeutics (MRKR) reported Liabilities from Discontinued Operations of 260280.0 for Q2 2023, down 96.3% quarter-over-quarter from 7039338.0 in Q4 2022.
Marker Therapeutics (MRKR) Liabilities from Discontinued Operations (2022 - 2023) Analysis & Trends
Marker Therapeutics (MRKR) has 2 years of Liabilities from Discontinued Operations data on file, last reported at 260280.0 in Q2 2023.
- Liabilities from Discontinued Operations for Q2 2023 came in at 260280.0, changed N/A year-over-year; the trailing twelve-month figure through Jun 2023 was 260280.0 (changed N/A YoY), and the FY2022 annual result was 7039338.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations slipped to 260280.0 in Q2 2023 per MRKR's latest filing, from 7039338.0 in the prior quarter.
- Over five years, Liabilities from Discontinued Operations peaked at 7039338.0 in Q4 2022 and troughed at 260280.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - |
| 10 | Marker Therapeutics | 27.04 Mn | 27.04 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 260,280.00 |
| Jun 30, 2023 | 260,280.00 |
| Dec 31, 2022 | 7.04 Mn |
| Dec 31, 2022 | 7.04 Mn |